Saiki Julie, the Chief Strategy Officer at Azora Therapeutics, Inc., has disclosed new stock transactions in a recent SEC filing. This report is significant as it sheds light on her ownership stake in the company, which may influence investor confidence and market perception.

Background

Azora Therapeutics, Inc., incorporated in Delaware, operates in the pharmaceutical preparations sector. The company is traded under the ticker symbol AZR. Saiki Julie has been actively involved in the company's strategic direction and decision-making processes.

What the Filing Says

In the filing dated November 4, 2026, Saiki reported the acquisition of 626,252 shares of common stock on November 2, 2026. Following this transaction, she now owns a total of 761,636 shares. Additionally, she acquired 626.252 shares of Series A Preferred Stock, which can convert into common stock under specific conditions.

Impact

This update may affect stakeholders and investors in Azora Therapeutics, as Saiki's increased ownership could signal confidence in the company's future. The pharmaceutical industry, particularly in the context of ongoing mergers and acquisitions, may also feel the impact of such executive transactions.

What's Next

The filing does not say what happens next.

Details of Transactions

In the recent filing, Saiki Julie reported two significant transactions on November 2, 2026. The first was the acquisition of 626,252 shares of common stock, which increased her total ownership to 761,636 shares. The second transaction involved the acquisition of 626.252 shares of Series A Preferred Stock, which is notable because each share of this preferred stock can convert into 1,000 shares of common stock, subject to certain conditions outlined in the Certificate of Designation.

Preferred Stock Conversion

The Series A Preferred Stock that Saiki acquired is particularly interesting as it will convert automatically within three days of the stockholders' approval of a proposal related to the issuance of common stock upon conversion. This conversion is tied to the terms of a Merger Agreement dated June 11, 2026, which involved Azora Therapeutics and its subsidiaries.

Ownership Structure

Following these transactions, Saiki Julie holds both common stock and preferred stock, with the total number of shares owned post-transaction amounting to 761,636 shares of common stock and approximately 1,225.977 shares of common stock equivalent from the Series A Preferred Stock. This dual ownership structure may provide her with significant influence over company decisions and future strategic directions.

Filing Context

While the filing provides detailed information about the transactions, it does not include insights into Saiki's future plans regarding her stock ownership or any potential implications for the company's strategy following these acquisitions. Additionally, there is no mention of her previous ownership levels or how this transaction compares to her past stock activity.